Abstract P2-01-23: Long-term follow-up of persistent breast dermopigmentation after sentinel lymph node identification using superparamagnetic iron oxide particles (SIENNA+(R))

Patients with breast cancer (BC) and those at high risk for BC are often reluctant to initiate Tamoxifen (Tam) due to potential adverse events (AEs) such as deep vein thrombosis (DVT), pulmonary embolus (PE), acute ischemic stroke (AIS), myocardial infarction (MI) and endometrial cancer (EC). Some decline this life saving therapy due to fear of AEs. AE rates from RCTs are low, but AE rates in the general population are not well documented.Methods: The MarketScanR database (2010-2013) was searched for patients aged 30-64 with a prescription of Tam active for more than 120 days. Patients with prior DVT, PE, AIS, MI or EC were excluded. ICD-9 codes for DVT, PE, AIS, MI and EC for inpatient and outpatient encounters were used to determine the frequency of AEs while on Tam. Patients taking Tam for prevention, DCIS or invasive cancer were included. Results were stratified by sex, age and time on Tam (in years). A random control group was created from the database utilizing patients age 30-64 with a levothyroxine prescription active for more than 120 days to calculate odds ratios (OR) for the AEs.Results: 67,887 patients on Tam, including 1622 males, were analyzed, for a total of 93,498 Tam Exposure Years. The control group included 2.4 million patients. The average age of Tam users was 48 (males), 50 (females). The average age of controls was 51 (males), 50 (females). Ages (%) represented in Tam users: 30-34 (2%), 35-44 (20%), 45-54 (52%), 55-64 (26%). The average time on Tam was 1...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research